Malaria and Sickle Cell Disease Treatment Market is expected to reach US$ 29,179.60 million by 2030

Malaria Segment, by Treatment, to Dominate Malaria and Sickle Cell Disease Treatment Market During 2022–2030 

According to our new research study on "Malaria and Sickle Cell Disease Treatment Market Size and Forecast (2020–2030), Global and Regional Share, Trends, and Growth Opportunity Analysis," the malaria and sickle cell disease treatment market size is expected to grow from US$ 4,691.87 million in 2022 and to reach a value of US$ 29,179.60 million by 2030; it is anticipated to record a CAGR of 26.5% from 2022 to 2030. Key factors driving the market growth are the increasing prevalence of malaria and sickle cell disease and rising government initiatives to raise awareness about malaria and SCD. However, the lack of sickle cell disease treatment options and the availability of counterfeit antimalarial drugs, followed by subsequent drug resistance, hinder the market growth.

A few major players operating in the malaria and sickle cell disease treatment market are increasingly focusing on the adoption of various strategies such as product innovations, launches, and approvals; R&D investments; and mergers and acquisitions in order to remain competitive. A few of these initiatives are mentioned below:

Malaria And Sickle Cell Disease (SCD) Treatment Market , by Geography, 2022 (%)

Source: The Insight Partners Analysis

• In April 2023, the US FDA offered Editas Medicine, Inc. an Orphan Drug Designation for its EDIT-301, which is used for the treatment of sickle cell anemia.
• In March 2023, AddMedica partnered with Abacus Medicine Pharma Services for the distribution of Siklos (hydroxyurea) in Belgium, the Netherlands, and Luxembourg. The therapy is suitable for patients aged two years and above.
• In October 2022, Pfizer Inc. completed the acquisition of Global Blood Therapeutics, Inc., which is involved in the development and commercialization of drugs to treat SCD.
• In July 2022, the Gavi Vaccination Project, funded by the Gates Foundation, introduced the Mosquirix vaccine developed by GlaxoSmithKline (GSK) for the first time in three African countries: Kenya, Ghana, and Malawi. This vaccine was reportedly the first malaria vaccine. This was a critical first step in introducing malaria vaccines in countries with moderate to high transmission rates of malaria caused by P. falciparum.
• In March 2022, tafenoquine, a novel drug used to treat a specific strain of malaria, was licensed in Australia by Medicines for Malaria Venture (MMV), which codeveloped the drug with GlaxoSmithKline (GSK) for children and adolescents. The drug is combined with the widely used antimalarial drug—chloroquine.
• In February 2022, Global Blood Therapeutics Inc. received marketing approval for Oxbryta for the treatment of hemolytic anemia caused by SCD in adult and pediatric patients (12 years and above) as monotherapy or in combination with hydroxycarbamide.
• In December 2021, Zydus Cadila announced the plan to develop its antimalarial drug ZY19489 with Medicines for Malaria Venture, which received US FDA approval. According to the company, the Phase I trial of ZY19489 demonstrated a long half-life and the potential for a single-dose cure for malaria. In a separate malaria challenge trial, strong antimalarial activity was displayed after a single oral dose of ZY19489.
• In January 2021, GSK, PATH, and Bharat Biotech (BBIL) declared that a product transfer agreement was signed for the malaria vaccine RTS,S/AS01E. The agreement included transferring the manufacturing of the RTS,S antigen portion of the vaccine and granting a license for all rights related to the malaria vaccine to BBIL. GSK retains production of the vaccine adjuvant (AS01E) and supplies it to BBIL.
• In May 2020, ADVANZ PHARMA Corp. Limited acquired Correvio Pharma Corp, a specialty pharmaceutical company. Under the acquisition, ADVANZ PHARMA achieved an immediate and direct commercial presence in France, Germany, Italy, Spain, and the Benelux region.

Therefore, the abovementioned strategic initiatives by the market players are expected to provide growth opportunities for the malaria and sickle cell disease treatment market in the coming years.

Cipla Ltd, Pfizer Inc, Sun Pharmaceutical Industries Ltd, Sanofi SA, GSK Plc, Novartis AG, Pfizer Inc, Emmaus Life Sciences Inc, AdvaCare Pharma USA LLC, VLP Therapeutics LLC, and Lupin Ltd are among the key companies operating in the malaria and sickle cell disease treatment market. The companies have been implementing various strategies that contribute to their growth and lead to various changes in the market. The companies have utilized both organic strategies (such as launches, expansion, and product approvals) and inorganic strategies (such as product launches, partnerships, and collaborations).

For instance, in October 2022, Pfizer Inc acquired Global Blood Therapeutics Inc. GBT brings a portfolio and pipeline that has the potential to address the full spectrum of critical needs for this underserved community. GBT discovered and developed Oxbryta (voxelotor), a first-in-class medicine that directly targets the root cause of SCD.

The report segments the malaria and sickle cell disease treatment market as follows:

The malaria and sickle cell disease treatment market is segmented on the basis of treatment, route of administration, distribution channel, and geography. Based on treatment, the market is divided into malaria and sickle cell disease. In terms of route of administration, the malaria and sickle cell disease treatment market is divided into oral and parenteral. Based on distribution channel, the market is categorized into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The malaria and sickle cell disease treatment market, based on geography, is segmented into North America (US, Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Africa, Nigeria, Congo, Tanzania, Uganda, Ghana, Kenya, Zambia, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com